Press releases

Lipum AB and QPS The Netherlands BV are pleased to announce a collaboration on the first-in-human study of SOL-116 with the aim of becoming a new treatment...
Lipum's biological drug candidate SOL-116 has successfully been manufactured under the regulations that apply to Good Manufacturing Practice (GMP). The...
2022-02-02 13:00 Lipum recruits scientist
Lipum's development work is in an intensive phase and an initial clinical phase 1 study is being prepared. Preclinical studies have previously shown promising...
2021-12-22 13:00 Lipum AB - report from extra general meeting Regulatory
Decision on the introduction of incentive programs for employees and consultants The meeting resolved that the program shall consist of a maximum of 72,500...
CEO Einar Pontén comments: “We are progressing according to plan and both toxicology- and safety studies, according to GLP, as well as GMP...
Flerie Invest AB is a reputable investment company with active ownership in biotechnology and pharmaceuticals. The company is controlled by Thomas Eldered...
With an ongoing program including toxicology- and safety studies, as well as GMP manufacturing of the drug candidate SOL-116, Lipum is in a late pre-clinical...
The Scientific Advisory Board of Lipum constitute an invaluable resource of experience from academic research to clinical practice within the field chronic...
Lipum will participate at the Naventus Life Science Summit, 29 September at Grand Hôtel in Stockholm. The event is organized by Naventus Corporate...
The drug candidate SOL-116 is an antibody and is thus a biological drug. In collaboration with Lipum's partner Abzena in San Diego, the development of...

Investor relations